New insights into the role of EMT in tumor immune escape

Molecular Oncology

Volumn 11, Issue 7, 2017, Pages 824-846

  Terry, Stéphane ^a   Savagner, Pierre ^b,c,d   Ortiz Cuaran, Sandra ^e,f,g,h   Mahjoubi, Linda ^a   Saintigny, Pierre ^e,f,g,h   Thiery, Jean Paul ^a,i,j   Chouaib, Salem ^a  

^a Faculty of Medicine University of Paris Sud   (France)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^c UNIV MONTPELLIER   (France)

^d Institut du Cancer Montpellier   (France)

^e CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^f UNIVERSITÉ DE LYON   (France)

^g CENTRE LÉON BÉRARD   (France)

^h UNIVERSITÉ LYON 1   (France)

ⁱ UNIVERSITÉ PARIS DIDEROT   (France)

^j NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

more..

Author keywords

antitumor immunity; EMT; immune escape; tumor microenvironment

Indexed keywords

BIOLOGICAL MARKER;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL HETEROGENEITY; CELL INTERACTION; CELL PLASTICITY; CYTOTOXIC T LYMPHOCYTE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL SYNAPSE; IMMUNOSUPPRESSIVE TREATMENT; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; NEOPLASM; PATHOLOGY;

ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85021323188     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1002/1878-0261.12093     Document Type: Review

References (203)

1. Abouzahr S, Bismuth G, Gaudin C, Caroll O, Van Endert P, Jalil A, Dausset J, Vergnon I, Richon C, Kauffmann A et al. (2006) Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc Natl Acad Sci U S A 103, 1428–1433.
2. Akalay I, Janji B, Hasmim M, Noman MZ, Andre F, De Cremoux P, Bertheau P, Badoual C, Vielh P, Larsen AK et al. (2013) Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res 73, 2418–2427.
3. Akalay I, Tan TZ, Kumar P, Janji B, Mami-Chouaib F, Charpy C, Vielh P, Larsen AK, Thiery JP, Sabbah M et al. (2015) Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression. Oncogene 34, 2261–2271.
4. Alix-Panabieres C, Mader S and Pantel K (2017) Epithelial-mesenchymal plasticity in circulating tumor cells. J Mol Med (Berl) 95, 133–142.
5. Allavena P and Mantovani A (2012) Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 167, 195–205.
6. Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M and Ghebeh H (2015) Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer 14, 149.
7. Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N et al. (2017) Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov 7, 264–276.
8. Anikeeva N, Somersalo K, Sims TN, Thomas VK, Dustin ML and Sykulev Y (2005) Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 102, 6437–6442.
9. Ansell SM (2017) Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res 23, 1623–1626.
10. Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C, Gabra H, Thiery JP and Huang RY (2016) The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. Sci Signal 9, ra97.
11. Ardiani A, Gameiro SR, Palena C, Hamilton DH, Kwilas A, King TH, Schlom J and Hodge JW (2014) Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process. Cancer Res 74, 1945–1957.
12. Bai J, Adriani G, Dang TM, Tu TY, Penny HX, Wong SC, Kamm RD and Thiery JP (2015) Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and beta2 integrin interactions. Oncotarget 6, 25295–25307.
13. Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V et al. (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 387, 1415–1426.
14. Barry M and Bleackley RC (2002) Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2, 401–409.
15. Barsoum IB, Smallwood CA, Siemens DR and Graham CH (2014) A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 74, 665–674.
16. Becht E, de Reynies A, Giraldo NA, Pilati C, Buttard B, Lacroix L, Selves J, Sautes-Fridman C, Laurent-Puig P and Fridman WH (2016a) Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res 22, 4057–4066.
17. Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautes-Fridman C, Fridman WH et al. (2016b) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17, 218.
18. Ben Safta T, Ziani L, Favre L, Lamendour L, Gros G, Mami-Chouaib F, Martinvalet D, Chouaib S and Thiery J (2015) Granzyme B-activated p53 interacts with Bcl-2 to promote cytotoxic lymphocyte-mediated apoptosis. J Immunol 194, 418–428.
19. Bommarito D, Martin A, Forcade E, Nastke MD, Ritz J and Bellucci R (2016) Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. Cancer Immunol Immunother 65, 355–366.
20. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E et al. (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373, 1627–1639.
21. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E et al. (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373, 123–135.
22. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH et al. (1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795–799.
23. van der Burg SH, Arens R, Ossendorp F, van Hall T and Melief CJ (2016) Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16, 219–233.
24. Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS et al. (2017) Clinical cancer advances 2017: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol, 35, 1341–1367.
25. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK et al. (2013) An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19, 279–290.
26. del Campo AB, Kyte JA, Carretero J, Zinchencko S, Mendez R, Gonzalez-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernack G, Garrido F et al. (2014) Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer 134, 102–113.
27. Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, Moreau P and LeMaoult J (2015) HLA-G: an immune checkpoint molecule. Adv Immunol 127, 33–144.
28. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K et al. (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 108, 7950–7955.
29. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W et al. (2014) Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5, 5241.
30. Chen J, Jiang CC, Jin L and Zhang XD (2016a) Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol 27, 409–416.
31. Chen XH, Liu ZC, Zhang G, Wei W, Wang XX, Wang H, Ke HP, Zhang F, Wang HS, Cai SH et al. (2015) TGF-beta and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells. Mol Immunol 65, 34–42.
32. Chen L, Yi X, Goswami S, Ahn YH, Roybal JD, Yang Y, Diao L, Peng D, Peng D, Fradette JJ et al. (2016b) Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology 5, e1234570.
33. Chester C, Fritsch K and Kohrt HE (2015) Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy. Front Immunol 6, 601.
34. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL et al. (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152–165.
35. Chretien AS, Le Roy A, Vey N, Prebet T, Blaise D, Fauriat C and Olive D (2014) Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front Immunol 5, 122.
36. Chua KN, Sim WJ, Racine V, Lee SY, Goh BC and Thiery JP (2012) A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. PLoS One 7, e33183.
37. Chung VY, Tan TZ, Tan M, Wong MK, Kuay KT, Yang Z, Ye J, Muller J, Koh CM, Guccione E et al. (2016) GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification. Sci Rep 6, 19943.
38. Cieply B, Riley PT, Pifer PM, Widmeyer J, Addison JB, Ivanov AV, Denvir J and Frisch SM (2012) Suppression of the epithelial-mesenchymal transition by Grainyhead-like-2. Cancer Res 72, 2440–2453.
39. Comrie WA and Burkhardt JK (2016) Action and traction: cytoskeletal control of receptor triggering at the immunological synapse. Front Immunol 7, 68.
40. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T et al. (2010) HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207, 2439–2453.
41. Crespo J, Sun H, Welling TH, Tian Z and Zou W (2013) T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 25, 214–221.
42. Dave B, Mittal V, Tan NM and Chang JC (2012) Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 14, 202.
43. Davis FM, Stewart TA, Thompson EW and Monteith GR (2014) Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci 35, 479–488.
44. Davoli T, Uno H, Wooten EC and Elledge SJ (2017) Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eeaf8399, https://doi.org/10.1126/science.aaf8399.
45. De Craene B and Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13, 97–110.
46. De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Perez-Garcia J, Masci G, Corsi F et al. (2015) MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget 6, 37269–37280.
47. Deng J, Wang L, Chen H, Hao J, Ni J, Chang L, Duan W, Graham P and Li Y (2016) Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget 7, 55771–55788.
48. Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpreville V, Validire P, Besse B and Mami-Chouaib F (2015) CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol 194, 3475–3486.
49. Dominguez C, Tsang KY and Palena C (2016) Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies. Cell Death Dis 7, e2380.
50. Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL and Weinberg RA (2017) Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res, Advance online publication. https://doi.org/10.1158/0008-5472.can-16-3292.
51. Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3, 991–998.
52. Dustin ML (2014) What counts in the immunological synapse? Mol Cell 54, 255–262.
53. Dustin ML, Chakraborty AK and Shaw AS (2010) Understanding the structure and function of the immunological synapse. Cold Spring Harb Perspect Biol 2, a002311.
54. Dustin ML and Long EO (2010) Cytotoxic immunological synapses. Immunol Rev 235, 24–34.
55. Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L, Planchard D et al. (2011) A direct comparison of Cell Search and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 105, 847–853.
56. Ferrand N, Gnanapragasam A, Dorothee G, Redeuilh G, Larsen AK and Sabbah M (2014) Loss of WISP2/CCN5 in estrogen-dependent MCF7 human breast cancer cells promotes a stem-like cell phenotype. PLoS One 9, e87878.
57. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C et al. (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375, 1856–1867.
58. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J et al. (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472–476.
59. Franciszkiewicz K, Le Floc'h A, Boutet M, Vergnon I, Schmitt A and Mami-Chouaib F (2013) CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions. Cancer Res 73, 617–628.
60. Fridman WH, Pages F, Sautes-Fridman C and Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12, 298–306.
61. Fritah A, Saucier C, De Wever O, Bracke M, Bieche I, Lidereau R, Gespach C, Drouot S, Redeuilh G and Sabbah M (2008) Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol 28, 1114–1123.
62. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J and Harlin H (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213, 131–145.
63. Galon J, Angell HK, Bedognetti D and Marincola FM (2013) The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39, 11–26.
64. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE et al. (2016) Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397–404 e399.
65. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L et al. (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372, 2018–2028.
66. Garrido F, Cabrera T and Aptsiauri N (2010) “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127, 249–256.
67. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD et al. (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21, 938–945.
68. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E et al. (2005) CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202, 1075–1085.
69. de Gramont A, Faivre S and Raymond E (2017) Novel TGF-beta inhibitors ready for prime time in onco-immunology. Oncoimmunology 6, e1257453.
70. Groh V, Wu J, Yee C and Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734–738.
71. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645–659.
72. Haber DA and Velculescu VE (2014) Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 4, 650–661.
73. Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, Koch M, Weitz J, Kloor M, Zoernig I et al. (2011) Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 17, 678–689.
74. Hamai A, Meslin F, Benlalam H, Jalil A, Mehrpour M, Faure F, Lecluse Y, Vielh P, Avril MF, Robert C et al. (2008) ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res 68, 9854–9864.
75. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369, 134–144.
76. Hamilton DH, Griner LM, Keller JM, Hu X, Southall N, Marugan J, David JM, Ferrer M and Palena C (2016) Targeting estrogen receptor signaling with fulvestrant enhances immune and chemotherapy-mediated cytotoxicity of human lung cancer. Clin Cancer Res 22, 6204–6216.
77. Hamilton DH, Huang B, Fernando RI, Tsang KY and Palena C (2014) WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. Cancer Res 74, 2510–2519.
78. Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J and Palena C (2013) Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 4, 1777–1790.
79. Hanrahan K, O'Neill A, Prencipe M, Bugler J, Murphy L, Fabre A, Puhr M, Culig Z, Murphy K and Watson RW (2017) The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer. Mol Oncol 11, 251–265.
80. Hasmim M, Noman MZ, Messai Y, Bordereaux D, Gros G, Baud V and Chouaib S (2013) Cutting edge: hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-beta1. J Immunol 191, 5802–5806.
81. He S, Yin T, Li D, Gao X, Wan Y, Ma X, Ye T, Guo F, Sun J, Lin Z et al. (2013) Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation. J Transl Med 11, 186.
82. Holzel M, Bovier A and Tuting T (2013) Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 13, 365–376.
83. Hsu DS, Lan HY, Huang CH, Tai SK, Chang SY, Tsai TL, Chang CC, Tzeng CH, Wu KJ, Kao JY et al. (2010) Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res 16, 4561–4571.
84. Huang RY, Guilford P and Thiery JP (2012) Early events in cell adhesion and polarity during epithelial-mesenchymal transition. J Cell Sci 125, 4417–4422.
85. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G et al. (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44.
86. Jazirehi AR, Baritaki S, Koya RC, Bonavida B and Economou JS (2011) Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res 71, 1406–1417.
87. Joffroy CM, Buck MB, Stope MB, Popp SL, Pfizenmaier K and Knabbe C (2010) Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res 70, 1314–1322.
88. Joyce JA and Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74–80.
89. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, Guo CC, Lotan Y and Kassouf W (2016) Bladder cancer. Lancet 388, 2796–2810.
90. Kang Y and Pantel K (2013) Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 23, 573–581.
91. Kardos J, Chai S, Mose LE, Selitsky SR, Krishnan B, Saito R, Iglesia MD, Milowsky MI, Parker JS, Kim WY et al. (2016) Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight 1, e85902.
92. Keith B and Simon MC (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129, 465–472.
93. Kerkar SP and Restifo NP (2012) Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 72, 3125–3130.
94. Khong HT and Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3, 999–1005.
95. Kim S, Koh J, Kim MY, Kwon D, Go H, Kim YA, Jeon YK and Chung DH (2016) PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Hum Pathol 58, 7–14.
96. Komdeur FL, Wouters MC, Workel HH, Tijans AM, Terwindt AL, Brunekreeft KL, Plat A, Klip HG, Eggink FA, Leffers N et al. (2016) CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRalphabeta+ CD8alphabeta+ T cells that can be targeted for cancer immunotherapy. Oncotarget 7, 75130–75144.
97. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL and Gatter KC (1996) Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 73, 148–153.
98. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA and Fearon DT (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330, 827–830.
99. Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A et al. (2012) Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 7, 306–315.
100. Kudo-Saito C, Shirako H, Ohike M, Tsukamoto N and Kawakami Y (2013) CCL2 is critical for immunosuppression to promote cancer metastasis. Clin Exp Metastasis 30, 393–405.
101. Kudo-Saito C, Shirako H, Takeuchi T and Kawakami Y (2009) Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15, 195–206.
102. Kumar V and Gabrilovich DI (2014) Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology 143, 512–519.
103. Kumar V, Patel S, Tcyganov E and Gabrilovich DI (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37, 208–220.
104. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY and Bapat SA (2009) Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27, 2059–2068.
105. Labelle M, Begum S and Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20, 576–590.
106. Laget S, Broncy L, Hormigos K, Dhingra DM, BenMohamed F, Capiod T, Osteras M, Farinelli L, Jackson S and Paterlini-Brechot P (2017) Technical insights into highly sensitive isolation and molecular characterization of fixed and live circulating tumor cells for early detection of tumor invasion. PLoS One 12, e0169427.
107. Lamouille S, Xu J and Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15, 178–196.
108. Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S et al. (2016) Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res 76, 227–238.
109. Le Floc'h A, Jalil A, Vergnon I, Le Chansac Maux B, Lazar V, Bismuth G, Chouaib S and Mami-Chouaib F (2007) Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med 204, 559–570.
110. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D et al. (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372, 2509–2520.
111. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC and Farace F (2011) Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer 105, 1338–1341.
112. Lee JC, Lee KM, Kim DW and Heo DS (2004) Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172, 7335–7340.
113. Ligtenberg MA, Witt K, Galvez-Cancino F, Sette A, Lundqvist A, Lladser A and Kiessling R (2016) Cripto-1 vaccination elicits protective immunity against metastatic melanoma. Oncoimmunology 5, e1128613.
114. Lim J and Thiery JP (2012) Epithelial-mesenchymal transitions: insights from development. Development 139, 3471–3486.
115. Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV et al. (2016) RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 22, 1499–1509.
116. López-Soto A, Huergo-Zapico L, Galvan JA, Rodrigo L, de Herreros AG, Astudillo A and Gonzalez S (2013) Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor. J Immunol 190, 4408–4419.
117. Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C et al. (2016) Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res 22, 3630–3642.
118. Mace EM, Dongre P, Hsu HT, Sinha P, James AM, Mann SS, Forbes LR, Watkin LB and Orange JS (2014) Cell biological steps and checkpoints in accessing NK cell cytotoxicity. Immunol Cell Biol 92, 245–255.
119. Mahoney KM, Rennert PD and Freeman GJ (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14, 561–584.
120. Majmundar AJ, Wong WJ and Simon MC (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40, 294–309.
121. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II et al. (2016) A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res 22, 609–620.
122. Malek R, Wang H, Taparra K and Tran PT (2017) Therapeutic targeting of epithelial plasticity programs: focus on the epithelial-mesenchymal transition. Cells Tissues Organs 203, 114–127.
123. Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, de Stanchina E and Massague J (2016) Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165, 45–60.
124. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Goncalves A, Andre P, Romagne F, Thibault G et al. (2011) Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 121, 3609–3622.
125. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715.
126. Mantovani A, Romero P, Palucka AK and Marincola FM (2008) Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371, 771–783.
127. Marvel D and Gabrilovich DI (2015) Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 125, 3356–3364.
128. Massague J (2008) TGFbeta in Cancer. Cell 134, 215–230.
129. Massard C, Michiels S, Ferte C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S et al. (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 Trial. Cancer Discov 7, 586–595, https://doi.org/10.1158/2159-8290.cd-16-1396.
130. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT et al. (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469.
131. McGranahan N and Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613–628.
132. Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL and Haanen J (2015) Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 15, 457–472.
133. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D et al. (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10, 8152–8162.
134. Milner JD and Holland SM (2013) The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Nat Rev Immunol 13, 635–648.
135. Mitra A, Mishra L and Li S (2015) EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 6, 10697–10711.
136. Mittal D, Gubin MM, Schreiber RD and Smyth MJ (2014) New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol 27, 16–25.
137. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF et al. (2015) Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33, 1430–1437.
138. Nantajit D, Lin D and Li JJ (2015) The network of epithelial-mesenchymal transition: potential new targets for tumor resistance. J Cancer Res Clin Oncol 141, 1697–1713.
139. Nieto MA, Huang RY, Jackson RA and Thiery JP (2016) EMT: 2016. Cell 166, 21–45.
140. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V and Chouaib S (2014) PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211, 781–790.
141. Noman MZ, Hasmim M, Messai Y, Terry S, Kieda C, Janji B and Chouaib S (2015) Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia. Am J Physiol Cell Physiol 309, C569–C579.
142. Noman MZ, Janji B, Abdou A, Hasmim M, Terry S, Tan TZ, Mami-Chouaib F, Thiery JP and Chouaib S (2017) The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. OncoImmunology 6, e1263412.
143. Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH and Heo DS (2016a) Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration. Clin Cancer Res 22, 2261–2270.
144. Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim JH, Jeon YK, Lee JS, Kwon SK, Hah JH et al. (2016b) PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget 7, 15901–15914.
145. O'Donnell JS, Long GV, Scolyer RA, Teng MW and Smyth MJ (2017) Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev 52, 71–81.
146. O'Donnell JS, Smyth MJ and Teng MW (2016) Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade? Genome Med 8, 111.
147. Orange JS (2008) Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 8, 713–725.
148. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP and Schlom J (2007) The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 13, 2471–2478.
149. Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L and Landi S (2016) Targeting hypoxic response for cancer therapy. Oncotarget 7, 13464–13478.
150. Parameswaran R, Ramakrishnan P, Moreton SA, Xia Z, Hou Y, Lee DA, Gupta K, deLima M, Beck RC and Wald DN (2016) Repression of GSK3 restores NK cell cytotoxicity in AML patients. Nat Commun 7, 11154.
151. Pattabiraman DR and Weinberg RA (2014) Tackling the cancer stem cells – what challenges do they pose? Nat Rev Drug Discov 13, 497–512.
152. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X et al. (2016) Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6, 202–216.
153. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, Andre P, Dieu-Nosjean MC, Alifano M, Regnard JF et al. (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71, 5412–5422.
154. Platten M, Wick W and Van den Eynde BJ (2012) Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 72, 5435–5440.
155. Pouyssegur J, Dayan F and Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437–443.
156. Prat A, Navarro A, Pare L, Reguart N, Galvan P, Pascual T, Martinez A, Nuciforo P, Comerma L, Alos L et al. (2017) Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma. Cancer Res, Advance online publication. https://doi.org/10.1158/0008-5472.can-16-3556.
157. Puhr M, Hoefer J, Schafer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H and Culig Z (2012) Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol 181, 2188–2201.
158. Punt CJ, Koopman M and Vermeulen L (2017) From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol 14, 235–246.
159. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S and Pistoia V (2004) Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6, 558–568.
160. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S et al. (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375, 1823–1833.
161. Restifo NP, Smyth MJ and Snyder A (2016) Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer 16, 121–126.
162. Ricciardi M, Zanotto M, Malpeli G, Bassi G, Perbellini O, Chilosi M, Bifari F and Krampera M (2015) Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells. Br J Cancer 112, 1067–1075.
163. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS et al. (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128.
164. Rooney MS, Shukla SA, Wu CJ, Getz G and Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61.
165. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y et al. (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920.
166. Ruffell B, Affara NI and Coussens LM (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol 33, 119–126.
167. Saleh MH, Wang L and Goldberg MS (2016) Improving cancer immunotherapy with DNA methyltransferase inhibitors. Cancer Immunol Immunother 65, 787–796.
168. Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, Mami-Chouaib F and Donnadieu E (2012) Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 122, 899–910.
169. Sanchez-Tillo E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A and Postigo A (2012) EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 69, 3429–3456.
170. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G and Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68, 989–997.
171. Saxena M, Stephens MA, Pathak H and Rangarajan A (2011) Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2, e179.
172. Schliekelman MJ, Taguchi A, Zhu J, Dai X, Rodriguez J, Celiktas M, Zhang Q, Chin A, Wong CH, Wang H et al. (2015) Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival. Cancer Res 75, 1789–1800.
173. Sharma P, Hu-Lieskovan S, Wargo JA and Ribas A (2017a) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723.
174. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S et al. (2017b) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18, 312–322.
175. Singh A and Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751.
176. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371, 2189–2199.
177. Takai S, Schlom J, Tucker J, Tsang KY and Greiner JW (2013) Inhibition of TGF-beta1 signaling promotes central memory T cell differentiation. J Immunol 191, 2299–2307.
178. Tam WL and Weinberg RA (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19, 1438–1449.
179. Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY and Thiery JP (2014) Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med 6, 1279–1293.
180. Terry S, Buart S, Tan TZ, Gros G, Noman MZ, Lorens JB, Mami-Chouaib F, Thiery JP and Chouaib S (2017) Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: consequences on susceptibility to cell-mediated cytotoxicity. OncoImmunology 6, e1271858.
181. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2, 442–454.
182. Thomas DA and Massague J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369–380.
183. Topalian SL, Taube JM, Anders RA and Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16, 275–287.
184. Tripathi SC, Peters HL, Taguchi A, Katayama H, Wang H, Momin A, Jolly MK, Celiktas M, Rodriguez-Canales J, Liu H et al. (2016) Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci U S A 113, E1555–E1564.
185. Tu E, Chia PZ and Chen W (2014) TGFbeta in T cell biology and tumor immunity: angel or devil? Cytokine Growth Factor Rev 25, 423–435.
186. Vasievich EA and Huang L (2011) The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm 8, 635–641.
187. Vivier E, Tomasello E, Baratin M, Walzer T and Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9, 503–510.
188. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, Capron F, Franco D, Pazzagli M, Vekemans M et al. (2000) Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 156, 57–63.
189. Webb JR, Milne K, Watson P, Deleeuw RJ and Nelson BH (2014) Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res 20, 434–444.
190. Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904–5912.
191. Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL and Cook GP (2011) Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One 6, e22842.
192. Wilson WR and Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11, 393–410.
193. Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG and Weiss SJ (2012) Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc Natl Acad Sci U S A 109, 16654–16659.
194. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW and Condeelis J (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67, 2649–2656.
195. Yao J, Caballero OL, Huang Y, Lin C, Rimoldi D, Behren A, Cebon JS, Hung MC, Weinstein JN, Strausberg RL et al. (2016) Altered expression and splicing of ESRP1 in malignant melanoma correlates with epithelial-mesenchymal status and tumor-associated immune cytolytic activity. Cancer Immunol Res 4, 552–561.
196. Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia XF, Sun X, Li GG, Hu QD, Fu QH et al. (2016) Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res 76, 818–830.
197. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J et al. (2016) Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17, 1283–1294.
198. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM et al. (2013a) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580–584.
199. Yu Y, Smoligovets AA and Groves JT (2013b) Modulation of T cell signaling by the actin cytoskeleton. J Cell Sci 126, 1049–1058.
200. Zhang J and Ma L (2012) MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev 31, 653–662.
201. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525–530.
202. Zitvogel L, Tesniere A and Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6, 715–727.
203. Zou W, Wolchok JD and Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8, 328rv324.